Summary
Cancer is a global problem with 14.1 million new cases occurring annually and an expected increase of 68% by 2030.
Ensuring effective and safe treatment remains a significant challenge for healthcare organisations. Studies have shown
proton therapy to be effective in treating many types of tumours, including tumours of the prostate, brain, head and neck,
central nervous system, lung, and gastrointestinal system as well as cancers that cannot be removed completely by surgery.
Proton therapy is the most advanced type of external-beam radiation therapy that uses protons at high energy to destroy
cancer cells. Proton therapy is routinely used for cancer treatment however it is limited by the sheer size and expense of the
systems. There are currently only 66 operational proton therapy facilities in the world, addressing only 3-5% of clinical
demand.
LPT is developing a proton therapy system that overcomes the presented challenges, saving up to 50% space and reducing
costs by up to 75%. LPT applies a patented approach to particle acceleration and beam delivery, combining nanotechnology
with Nobel- Prizewinning ultra-high-intensity lasers and advanced magnetics. These technological breakthroughs
enable meaningful reduction
in the size, complexity and cost of proton therapy systems that will enable the widespread adoption of proton therapy both
across Europe and globally.
The technology is supported by the Horizon 2020, SME instrument. The LPT project aims to take the innovation to the next
level through the collaboration of strong industrial and academia players. Together, HIL applied medical, THALES
Optronique and INFN, will achieve fundamental milestones in the development of the commercial system, namely PT-100.
This system will be constructed based on the Alpha system (developed with the support of SME instrument), with a higher
repetition rate and proton flux to enable clinical use and wide market adoption.
Ensuring effective and safe treatment remains a significant challenge for healthcare organisations. Studies have shown
proton therapy to be effective in treating many types of tumours, including tumours of the prostate, brain, head and neck,
central nervous system, lung, and gastrointestinal system as well as cancers that cannot be removed completely by surgery.
Proton therapy is the most advanced type of external-beam radiation therapy that uses protons at high energy to destroy
cancer cells. Proton therapy is routinely used for cancer treatment however it is limited by the sheer size and expense of the
systems. There are currently only 66 operational proton therapy facilities in the world, addressing only 3-5% of clinical
demand.
LPT is developing a proton therapy system that overcomes the presented challenges, saving up to 50% space and reducing
costs by up to 75%. LPT applies a patented approach to particle acceleration and beam delivery, combining nanotechnology
with Nobel- Prizewinning ultra-high-intensity lasers and advanced magnetics. These technological breakthroughs
enable meaningful reduction
in the size, complexity and cost of proton therapy systems that will enable the widespread adoption of proton therapy both
across Europe and globally.
The technology is supported by the Horizon 2020, SME instrument. The LPT project aims to take the innovation to the next
level through the collaboration of strong industrial and academia players. Together, HIL applied medical, THALES
Optronique and INFN, will achieve fundamental milestones in the development of the commercial system, namely PT-100.
This system will be constructed based on the Alpha system (developed with the support of SME instrument), with a higher
repetition rate and proton flux to enable clinical use and wide market adoption.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/965586 |
| Start date: | 01-12-2020 |
| End date: | 30-11-2022 |
| Total budget - Public funding: | 3 745 940,00 Euro - 2 697 045,00 Euro |
Cordis data
Original description
Cancer is a global problem with 14.1 million new cases occurring annually and an expected increase of 68% by 2030.Ensuring effective and safe treatment remains a significant challenge for healthcare organisations. Studies have shown
proton therapy to be effective in treating many types of tumours, including tumours of the prostate, brain, head and neck,
central nervous system, lung, and gastrointestinal system as well as cancers that cannot be removed completely by surgery.
Proton therapy is the most advanced type of external-beam radiation therapy that uses protons at high energy to destroy
cancer cells. Proton therapy is routinely used for cancer treatment however it is limited by the sheer size and expense of the
systems. There are currently only 66 operational proton therapy facilities in the world, addressing only 3-5% of clinical
demand.
LPT is developing a proton therapy system that overcomes the presented challenges, saving up to 50% space and reducing
costs by up to 75%. LPT applies a patented approach to particle acceleration and beam delivery, combining nanotechnology
with Nobel- Prizewinning ultra-high-intensity lasers and advanced magnetics. These technological breakthroughs
enable meaningful reduction
in the size, complexity and cost of proton therapy systems that will enable the widespread adoption of proton therapy both
across Europe and globally.
The technology is supported by the Horizon 2020, SME instrument. The LPT project aims to take the innovation to the next
level through the collaboration of strong industrial and academia players. Together, HIL applied medical, THALES
Optronique and INFN, will achieve fundamental milestones in the development of the commercial system, namely PT-100.
This system will be constructed based on the Alpha system (developed with the support of SME instrument), with a higher
repetition rate and proton flux to enable clinical use and wide market adoption.
Status
SIGNEDCall topic
EIC-FTI-2018-2020Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
